The National Centre for Research and Development

search

 

CORE; Programme area: health; ID: 197969

print
A A A

 

Project title: Highly cytotoxic FGF2-conjugates in targeted therapy for FGFR-expressing cancers

 

Acronym: FGF2CON

 

Project Promoter: University of Wrocław\Faculty of Biotechnology

 

Polish partners: -

 

Norwegian Partners: Oslo University Hospital, Institute for Cancer Research; Department of Biochemistry; Oslo University Hospital, Institute for Cancer Research; Department of Tumor Biology

 

Project cost (EUR): 956 094

 

Grant amount (EUR): 956 094

Duration: 37 months

 

 

www: http://www.protein.pl/

 

 

Project summary:

Cancer treatment represents a crucial unmet need of current medicine. Particular emphasis is placed on targeted cancer therapies that are based on drugs that block the growth and spread of cancer cells by interfering with specific macromolecules, which are deregulated and play important role in tumor progression.
The main goal of this project is to develop a novel targeted therapy against different types of cancers overexpressing fibroblast growth factor receptors (FGFRs). We propose an unexplored approach based on the FGF2 molecule fused to a highly efficient cytotoxic drug to establish a delivery technique for effective killing of cancer cells. Our strategy is similar to construction of antibody drug conjugates (ADCs), which are showing clinical efficacy in cancer treatment. However, instead of antibodies we will use the engineered growth factor as a delivery molecule specifically directing cytotoxic drug to cancer cell by binding to FGF receptors.

 

The National Centre for Research and Development
47a Nowogrodzka Str.,  00-695 Warszawa  office: +48 22 39 07 401  fax: +48 22 20 13 408
REGON: 141032404  NIP: 701-007-37-77

realizacja: Ideo powered by CMS Edito